MOGAT is a phase II clinical trial combining mogamulizumab + total skin electron beam (TSEB). PI of this proposal is the general study coordinator of the trial. Translational research linked to this trial needs finantial support. Hipotesis: Predictive biomarkers for response/resistance to mogamulizumab+/-TSEB can be found Objectives: To identify factors in the skin and/or blood that can predict response or resistance to mogamulizumab +/- TSEB. To study a panel of immunohistochemistry in MF biopsies at 3 different timepoints of the clinical trial. To study changes in the tumour microenvironment of CTCL caused by mogamulizumab+/- TSEB. To study gene expression on lesional MF skin. To analyze mutational landscape of 261 genes important for T-cell biology. To evaluate the use of liquid biopsies in CTCL to identify factors that can predict response or resistance mogamulizumab+/- TSEB. To correlate all previous findings with clinical outcome of the trial. Methods: Projected accrual: 39 patients. Lesional skin samples will be collected at baseline, before TSEB and at progression. Blood samples (20 mL) will be collected at baseline, before TSEB, after TSEB and at progression. A buccal swab will be collected at baseline. Samples will be used for 1: Immunohistochemistry with a panel of 25 markers, 2: Gene expression analysis (Nanostring nCounter® system) using a customized panel of 350 genes; 3: Gene sequencing, targetting 261 genes of known biological relevance in T cells, studied by target enrichment and deep sequencing 4: Liquid biopsy analysis, studying exosomes and circulating cfDNA
Micosis fungoide. Mogamulizumab. Radioterapia cutánea total con electrones. Linfoma cutáneo de células T. Resistencia a fármacos. Oncología de precisión
Acción Estratégica en Salud (AES)
01/01/2023 - 30/06/2027
PABLO LUIS, ORTIZ ROMERO
FUNDACION INVESTIGACION BIOMEDICA HOSPITAL 12 DE OCTUBRE
INSTITUTO DE INVESTIGACION HOSPITAL 12 DE OCTUBRE (i+12)
MADRID
MADRID
202,000 €